NCT06978647
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
See at-risk trials from China Immunotech (Beijing) Biotechnology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from May 19, 2026 to May 19, 2027
- Eligibility criteria expanded, about 44 words
- Secondary endpoints: details revised at 1 of 6 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Treatment-Emergent Adverse Events
Timeframe: The efficacy endpoint evaluation for 2, 4, 8, 12 weeks, AEs observation will be follow-up for 24 weeks. The observation period is extended to 52 weeks.
Secondary (6)
Efficacy Evaluation in relapsed/refractory autoimmune diseases
Maximum Plasma Concentration of YTS109 (Cmax)
Area Under the Plasma Concentration-Time Curve (AUC) of YTS109
Time to Reach Maximum Plasma Concentration (Tmax) of YTS109
PD Biomarker Level Change (Cytokines Concentration)
Show 1 moreShow less
PD Biomarker Level Change (B cells Quantification and Phenotypic)
Arms and interventions
YTS109 cellExperimental
Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.
Drugs: YTS109 cell
Sites
1 site in 1 country
- The First Medical Center of Chinese PLA General HospitalBeijing, Beijing Municipality, China